IO Biotech announced that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company's investigational immune-modulating cancer vaccine, in combination with pembrolizumab in patients with BCG-unresponsive or intolerant, non-muscle invasive bladder cancer (NMIBC). This is one of five investigator-initiated trials IO Biotech is supporting to evaluate IO102-IO103 in combination with different checkpoint inhibitor-based regimens across a variety of cancer types.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.233 USD | -1.36% | +4.49% | -34.41% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.41% | 81.23M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center